Arcturus Therapeutics Holdings Inc. (ARCT) · Aug 25, 2026 · Other events

Arcturus schedules ARCT-810 poster, but no new clinical data yet

No new info — Poster notice confirms an expected presentation; additional data and regulatory plan remain due later this quarter

Arcturus will present ARCT-810 OTC-deficiency data at SSIEM, but the filing adds no results; fuller data and a regulatory plan remain pending.

The market was already expecting an ARCT-810 update this quarter. Arcturus said on August 6, 2026 that Phase 2 enrollment and dosing were complete, with data and a regulatory plan expected in the third quarter, so this scheduled poster is confirmation rather than a surprise.

The filing announces a presentation, not a clinical result. Arcturus says it will present a poster on the therapy’s impact on dietary intake and biochemical data in adolescents and adults with OTC deficiency. 〔0〕 The supplied filing provides no efficacy, safety, biomarker, or regulatory numbers to change the investment case.

The actual catalyst remains the later-quarter data and regulatory update. The filing explicitly defers both items: 〔1〕 Against the standing expectation, today’s 8-K adds timing and venue—but no new information—making the appropriate read neutral.

What to watch next

ARCT-810 data and regulatory plan, later this quarter

Original filing on SEC EDGAR

More Arcturus Therapeutics Holdings Inc. news

Arcturus schedules ARCT-810 poster, but no new clinical data yet | ARCT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.